



Gut Microbiota's Impact on Neurological Health as The Gut-Brain Axis

Shivani Chib ^{1*}, Loiy Elsir Ahmed Hassan ², Saikat Mukherjee ³

Abstract

The Gut-Brain Axis (GBA) represents a dynamic and intricate bidirectional communication network that intertwines the gut and the brain. Studies reveal the significant influence of gut microbiota on the central nervous system and neurological health. In order to fully understand the basic connections between gut microbiota and brain health, this review will focus on the underlying processes, possible clinical consequences, and changing field of microbiome-based therapies. The gut microbiota, a diverse range of bacteria, viruses, fungus, and other microbes, is found in the human gut, which functions as a dynamic ecosystem. Despite being mostly recognized for their functions in nutrition metabolism and digestion, these microbes are increasingly important for controlling the central nervous system. Neuroactive substances, such as neurotransmitters and short-chain fatty acids, which are produced in large quantities by the gut microbiota, have a profound impact on behavior, mood, and cognitive performance. Furthermore, the "leaky gut" theory suggests that the immune system and gut microbiota interact, which has implications for a variety of neurological disorders, including neuroinflammatory illnesses. Probiotics, prebiotics, and

fecal microbiota transplantation (FMT) have emerged as promising approaches to modify the gut microbiota's composition and restore homeostasis in a range of neurological conditions. Emerging research suggests that these therapies may be beneficial for a variety of ailments, including anxiety, depression, autism spectrum disorders, and neurodegenerative diseases. Personalized interventions are necessary due to the highly individualised link between gut microbiota and brain health. The precise mechanisms underpinning the influence of gut microbiota on CNS function continue to be an active area of research.

Keywords: Gut-Brain Axis, Microbiota, Neurological Health, Signaling Pathways, Microbiome-based Therapies

Introduction

The drastic changes in the modern environment and way of life pose a major threat to human health. One of the main issues facing the world today is the enormous rise in a wide spectrum of neurological illnesses. It has become clear during the past ten years that the gut microbiota has a possible contribution to brain function through microbial metabolites' mediation of signaling pathways (Iannone et al., 2019; Grokowska et al., 2019). At the nexus of microbiology and neuroscience, significant research, primarily carried out in the last ten years, has demonstrated dynamic relationships between animal populations of microbes that support the development of and how the nervous systems function. These connections encompass neurological, immunological, and chemical interactions, although they are

Significance | This review discussed the gut-brain connections to suggest therapies for neurological disorders; microbiome modulation shows promise in personalized treatments for diverse ailments.

*Correspondence: Shivani Chib, Central University of Punjab, Jammu & Kashmir, India. E-mail: shivani.pharmacology11@gmail.com

Editor Md Asaduzzaman Shishir. And accepted by the Editorial Board Jan 17, 2024 (received for review Nov 22, 2023)

Author Affiliation:

¹ Central University of Punjab, Jammu & Kashmir, India

² Bristol-Myers Squibb, Redwood City, USA

³ Department of Biochemistry, Manipur University, Imphal, Manipur, India.

Please cite this article:

Shivani Chib, Loiy Elsir Ahmed Hassan, Saikat Mukherjee. (2024). Gut Microbiota's Impact on Neurological Health as The Gut-Brain Axis, *Microbial Bioactives*, 7(1), 1-12, 9375

intricate, are essential to people's health and our knowledge of neurological conditions (Morais et al., 2021). The gastrointestinal (GI) tract's gut microbiota regulates cells in nearby and distant organs, including the brain, and is crucial to the host's overall health. In the gut-brain axis (GBA), bidirectional transmission takes place as a two-way communication channel between the host's neurological system and gut. The immune system, brain networks, and hormones can all transmit this information, supporting the intestinal flora. According to Collins et al. (2012), bidirectional transmission in the GBA controls the innate and adaptive immune systems, preserves a mutualistic relationship with the host, and governs brain dysfunction mechanistically. This axis encompasses multiple pathways, including the immune system, the endocrine system, the hypothalamic-pituitary-adrenal axis (HPA), the autonomic and enteric nervous systems, and the metabolites produced by the microbiota (Blaser, 2017; Burberry et al., 2020). By creating microbial compounds and neurotransmitters for communication with host cells, such as intestinal epithelial cells (IECs) and immune cells, a healthy gut microbiota helps the host. Modifications the synthesis of microbial metabolites and the gut microbiota have been connected to several immune-related neurological conditions, including neurodegeneration, emotional problems, and developmental disorders dysfunction. The organ that controls every aspect of a person's as well as for managing it. It is made up of several, varied groups of cells, both neuronal and nonneuronal, joined by very complex structural networks (Deidda and Biazzo, 2021).

Over 98% of the bacteria in our bodies live in the gastrointestinal tract (GI). The specific bacteria that exist and live in the gut are referred to as the "gut microbiota" (Ma et al., 2019). The advancement of omics methods has aided in the knowledge of the gut microbiota as a major regulator of the brain and gut's interactions (Bhattarai et al., 2021). Research on humans and animals has shown that the gut microbiota may affect how the brain develops hormones, immunological variables, and other chemicals that affect behavior and cognition. Metabolites, indicating that altering the microbiota in the gut may help with or maybe treat brain illnesses (Lee et al., 2011). Recently, it has become clear that the gut-brain axis plays a critical role in both the development of normal brain function under physiologically normal circumstances and the control of normal brain functioning. As a condition or risk factor, neuropathological disorders (Ma et al., 2019). Nevertheless, there isn't much evidence to support the processes behind the connections between the brain and gut microbiome illnesses (Martin and others, 2018). In order to discover and confirm biological mechanisms of action that have the actual potential to cure human diseases, new technologies are being developed to go beyond correlative research sickness. This paper examines the relationship that exists between the stomach

and the signaling pathways in the brain. Additionally, we talk about the role of bacteria and neurological conditions such mood disorders, neuropsychiatric disorders (such as ADS and schizophrenia), (depression and anxiety), as well as neurological conditions (PD, AD, MS as well).

Gut microbiota-brain axis

The digestive system is colonized by bacteria, viruses, archaea, and eukaryotic organisms that make up the gut microbiome. It is estimated that the gut microbiota is 100–150 times more genes identified in the human intestines and more than the human genome include over 7,000 different kinds of bacteria, either gram-negative or gram-positive Firmicutes, which includes the kind Clostridium, Eubacterium, and Lactobacillus), as well as gram-negative. Most bacteria are classified as Bacteroidetes (including Bacteroides & Prevotella) (Elingrod and Flowers, 2015). The gut microbial population is mostly composed of the following five phyla: Verrucomicrobia, Actinobacteria, Proteobacteria, Firmicutes, and Bacteroidetes (The Consortium for the Human Microbiome Project (2012). People's age, diet, and genes, environment, and gender all affected the makeup of the bacteria in their stomach (Takagi et al., 2019). gut dysbiosis in humans .Numerous disorders have been linked to the microbiome (Perry et al., 2016). Differences in the richness and frequency of the microbial community (all taxa and species) that make up the gut flora have been linked to gut dysbiosis in both animal and human research on aberrant immune response, inflammation, and brain protein aggregation studies of dysregulation, decreased neuronal and synaptic activity, and AD (Cryan and others, 2020; Gubert and others, 2020).

The gut microbiota's potential to influence brain-related functions implies that it stimulates the synthesis of immune components that target the enteric nervous system (ENS) as well as the central nervous system (CNS), including as inflammatory mediators and cytokines (Wood and Galligan, 2004). A part of the peripheral nervous system is the autonomic nervous system, which controls physiological functions not susceptible to intentional command. It coordinates essential visceral functions complimenting exchanges between the understanding and nerve systems that are parasympathetic. The discovery of the ENS, a branch of the autonomic nervous system, significantly increased our understanding of the bidirectional communication between the CNS and the neural system. Occasionally referred to as the "second brain in the body," is kept in a healthy state with the help of intestinal neurones and links to the central nervous system (Rao and Gershon, 2018). The millions of neurons present in the mucosa make up the ENS throughout the digestive system. These neurons are in charge of maintaining the balance of intestinal function. The quickest path to the vagus nerve serves as a conduit

for information between the brain and the gut (la Fuente-Nunez et al., 2018).

Communication between the brain and the bowel takes place via the gut-brain axis (GBA), a complex bidirectional communication network (Figure 1; Sudo Skonieczna Zydecka et al., 2018; Rao and Gershon, 2018; et al., 2004). The autonomic nerve system is involved in the pathways of communication. [such as the vagus nerve and the enteric nervous system (ENS)], the hypothalamic-pituitary-adrenal system, and the neuroendocrine system the immunological system, the HPA axis, and metabolic pathways (Duvallat, 2017). A number of metabolites and neurotransmitters, such as short-chain fatty acids, secondary bile acids, and essential vitamins (Yano et al., 2015; O'Keefe, 2016), and amino acids (Mittal, 2016; Ellwardt et al., 2016; Engelhardt et al., 2016) alter several immune system pathways (Baj et al., 2017), which therefore impact behavior, thought processes, and learning, motor function, and neurological conditions (Jenkins et al., Kennedy and colleagues, 2017; Feng and colleagues, 2020). The brain-gut axis has dubbed the GMB axis because it seems to control the immune digestive tract, behavior, CNS functions, and stress response (Savignac and others, 2011).

How the gut microbiota affects the Brain

Numerous chemical signaling routes, such as direct neuronal, immunological, and endocrine pathways, are used by the CNS and ENS to interact with one another (Yoo and Mazmanian, 2017). The gut-brain axis is a web of relationships including several biological systems that enable two-way conversation between the brain and gut flora and is essential for preserving the animal nervous, gastrointestinal, and microbiological systems (Martin et al, 2018). The gut microbiota influences the brain through the endocrine, immunological, and metabolic systems in addition to the nervous system (the gut-brain neuroanatomical route) (Montiel-Castro, 2012). Greater focus is on the gut microbiota-brain axis because the gut microbiota may be utilized to shed light on the role of bacteria as an independent variable that has been purposefully altered (Al Omran 2014). Microbes can influence the neural system's development ages, develops, and preserves homeostasis, for instance, by changing how N-methyl D-aspartate (NMDA) and neurotrophic factors interact the hippocampus expresses receptor subunits (Bercik et al., 2011). The primary means via which the microbiome can impact the nervous system's growth and operation include biological networks, including transmission via direct and indirect neural networks, immunological system, chemical transmitters, and hormone routes, as seen in Figure 2.

Microbiota and neurotransmitters

Through "direct" and "indirect" chemical interactions with the neurological system, gut microorganisms can assist control body processes and change behavior in their animal host [Morais and

others, 2021). It is possible for microbes to produce certain neuroactive substances themselves, in addition to stimulating the host's synthesis of more metabolites and neurotransmitters which control gut-brain communication (Poutahidis et al., 2013). The proper maturation, activation, and growth of microglia—the brain's innate immune cells—requires the microbiome as well (Zheng and others, 2020). It appears that microglia train the immune system is controlled by cues from microbiological metabolism since giving short-chain fatty acids (SCFAs) produced by bacteria to Microglial form and function are restored in germ-free (GF) mice (Erny and others, 2015). chemicals produced by microbes communicating with the brain. The digestive tract produces neurotransmitters such dopamine, serotonin, norepinephrine, glycine, and gamma-aminobutyric acids microbiome, each of which has a unique effect on the brain. Acidobutyric acid GABA acid. These neurotransmitter imbalances can result in illnesses including anxiety, PD, AD, and autism spectrum disease, depression problems, among others (Chen et al., 2021). For instance, Bifidobacterium infantis raises blood plasma tryptophan levels, which influences the transmission of central serotonin; Lactobacillus and Bifidobacterium may both create GABA, Noradrenaline can be generated by Bacillus, Escherichia, and Saccharomyces species, Streptococcus can generate serotonin species of Enterococcus, Escherichia, and Candida; dopamine may be generated by microorganisms; moreover, acetylcholine may be generated by Lactobacillus (Lyte, 2014). SCFAs, a type of direct signaling, are Lipids generated by intestinal microbes through the fermentation of Dietary fiber that have the ability to influence the immune system, Epigenetics, and neuroplasticity in the CNS (Dalile et al., 2019)

Orphan G protein-coupled receptors (GPCRs) bind endogenously to SCFAs, and intracellular SCFAs inhibit histone deacetylases to control gene expression. In addition, Vagal afferents and SCFA interaction influences inflammation and hormone control. The ways in which SCFAs interact with certain theory is supported by biological mechanisms and gut-brain communication connections that SCFAs can be quite important in GMB communication (Dalile, et al, 2019). By altering the endocrine signals generated by enteroendocrine cells (EECs) in the gut epithelium, gut microbiota can influence their host's appetite and eating habits. This entails the synthesis of glucagon-like peptide 1 (GLP1), a hormone (El Aidy and Arresti Sanz, 2019). The gut's microbiome can generate neurotransmitters independently and have the ability to activate the production of these substances in the animal hosts. For instance, a many microorganisms, such as Bacteroides, Escherichia spp. It is known that Bifidobacterium and related species produce the glutamatergic neurotransmitter (Strandwitz et al., 2019). SCFAs, 5-HT, dopamine, butyric acid, gamma amino acids, and gamma amino acids are all produced by gut bacteria (Forsythe et

al., 2014) interoperable across microorganisms (Forsythe et al., 2014). The abdomen, notably intestine cells, are able to produce significant quantities of 5-HT. It has an impact on the brain. Furthermore, microorganisms' enzymes can produce neurotoxins such as ammonia and D-lactic acid (Manicassamy & Associates, 2010). These neuroactive metabolites include amino acids (tryptophan, for example) and neurotransmitters GABA, dopamine, noradrenaline, and serotonin. T lipopolysaccharide (LPS), tyramine, and short-chain fatty acids Trimethylamine-N-oxide, long-chain fatty acids (LCFAs), and (SCFAs) (TAMO) and, either directly or indirectly, polysaccharide A (PSA) stimulate the brain's peripheral immune cells to migrate there and are believed to induce neuroinflammation and affect brain functioning (Harms and others, 2018). In fact, it is difficult to evaluate how much microbial metabolism directly affects CNS activity, in part because we do not fully understand the average rate of transport for numerous microbial metabolites into the brain (Muller et al., 2020).

Endocrine pathway

By controlling the synthesis of gut hormones, SCFAs can modify the way the gut-brain axis functions. The process involves SCFAs activating G protein-coupled receptors (GPCRs) in the colon underpinning the synthesis of these digestive hormones, which improves the release of glucagon-like peptide 1 (GLP1) and peptide YY (PYY) from intestinal endocrine L cells (Psichas et al., 2015). These hormones can then have an impact on emotions, recall, and education. By using free fatty acid SCFAs can communicate with the brain by directly activating their receptors (FFARs) vagal afferents, according to Dalile et al. (2019). GLP1 is receptor-rich all around the body and can impact how the brain operates through both humoral and neural pathways, such as the central nervous system, PNS, as well as the heart, lungs, intestines and pancreas (Alvarez et al., 2005). GLP1 has been linked to improved neuroplasticity and neuroprotection in the hippocampus (McClellan et al., 2011; Porter), as well as improved memory and learning in mice (Isaacson et al., 2011), in decreased β amyloid and in animal models of AD plaques and the activation of microglia (McClellan et al., 2011). One more PYY, anorexic neuropeptide, decreases hunger and inhibits stomach movement. Apart from the L cells in the distal gastrointestinal tract. The colon, ileum, pituitary gland, and hypothalamus secrete it the human brain's greatest concentrations of PYY expression, which is expressed all across the brain, according to Morimoto et al. (2008).

Immune pathway

The gut microbiota and the central nervous system both have a direct and indirect impact on the immune system. The growth and operation of the gut microbiome are significantly influenced by the Zheng et al. (2020) discuss the peripheral immune system. It is the microbiota Essential for the growth and activation of the

innate immune brain's cells (Abdel-Haq et al., 2019). The pathogenesis of Immune reactions and mental illnesses can both Inflammation (Raison and Miller, 2016). Neurocircuits that control motivation, motor activity, and mood are impacted by CNS-cytokine interactions, which also have an impact on other aspects of brain function (Capuron and Miller, 2011). In addition, via the immune system as a whole and the brain, the gut microbiome, and circulating cytokines Hold conversations (Hsiao et al., 2013). Immune cells enter directly either they can create cytokines and cross the BBB to enter the CNS the brain's chemokines (Morais et al., 2021). A cytokine is chemicals produced in the gut that are able to pass through the bloodstream and, in some circumstances, impact the brain regions, including the hypothalamus (El Aidy et al., 2014). Microglial activation has been connected to several mental illnesses, including major depressive disorder, schizophrenia, autistic spectrum disorder, and obsessive-compulsive disorder, dysregulation (Frick and colleagues, 2013). The direct effects of SCFAs on immune modulators and immune cells to sustain consistency. The impact of SCFAs on the mucosa of the intestine. The description of immunity by Corrêa-Oliveira et al. (2016) is excellent. Nevertheless, SCFAs can potentially affect the peripheral immunological system, influencing mental processes. By elevating the preventing the spread of microorganisms over the gut barrier and Bacterial metabolites or through SCFAs' direct interaction with immune cells that may reduce the amount of neuroinflammation in the systemic inflammation may be lessened in the brain (Dalile et al., 2019).

Neuronal pathways for gut brain Interactions

Through neural connections, the gut and brain are physically connected. Of these neuronal networks, the vagus nerve which arises from the brainstem and innervates—is the most important. The ENS and the digestive system (Yoo and Mazmanian, 2017). The strongest and best-established connection between the stomach and the another channel by which the gastrointestinal tract can the brain and microorganisms can interact (Fülling et al., 2019). Within the digestive tract, the vagus nerve innervates almost the whole nerve, of which 20% are efferent fibers and 80% are afferent. What's known as the vagal. Several levels of the digestive system are innervated by afferent nerve terminals. mucosal afferents terminate in the lamina propria of the intestinal wall, although mucosa of the intestines (Waise et al., 2018). The sensory vagal receptors foods, bacterial metabolites, inflammatory substances, additionally regulatory gut peptides to transfer signals to the central nervous system (De Lartigue et al., 2011).

The feelings of anxiety brought on by ongoing gut inflammation were lessened by long-term Bifidobacterium longum NCC3001 therapy (Bercik et al., 2011b). The outcomes of these trials were removed when the integrity of the vagus nerve was weakened by




Figure 1. The microbiota-gut-brain axis. Several routes, including the immunological system, neuroendocrine system, enteric nervous system (ENS), circulatory system, and vagus nerve, mediate the bidirectional connection between the brain and gut bacteria. The paths that these pathways comprise a variety of neuroactive chemicals, such as peptides, gut hormones, microbial-derived metabolites, and neuroactive substances. Metabolite entry into the brain can impact neurodevelopment and neurodegeneration in a variety of disorders, including multiple sclerosis, Parkinson's disease, Alzheimer's disease, central nervous system cancers, stroke, schizophrenia, anxiety, depression, and autistic spectrum disorder.




Figure 2. Communication channels between gut microbiota and brain. There are several direct and indirect gut-brain axis mechanisms that mediate the relationship between the central nervous system (CNS) and gut bacteria. These comprise the neuroactive route, which includes neurotransmitters and neuroactive metabolites; the neural pathway [enteric nervous system]; and the immunological pathway, which includes cytokines, short-chain fatty acids, and microbiological metabolites. Spinal nerves, vagus nerve, and nervous system (Sgritta et al., 2019).

vagotomy (Bercik et al., 2011b; Bravo et al., 2011). Microbial metabolites also possess the ability to directly turn on the neurons. The FXR and TGR5 receptors are expressed in despite the fact that healthy people have low or amounts of undetectable bile acid in various tissues (Huang and others, 2016). Numerous research projects have determined the superior cervical G protein-coupled receptor 41 is found in ganglions (GPR41) and receptors for the free fatty acid receptor 3 (FFAR3) (Kimura et al., 2011), submucosal and prevertebral ganglia (Won et al., 2013), neurons in the myenteric ganglia (Nohr et al., 2013). sympathetic nervous system comprising the vagal ganglion and sympathetic trunks of the thoracic and lumbar regions (Nohr et al., 2015), indicating that microbes may activate neurons produced SCFAs. Colonic epithelium's neural innervation is decreased in GF mice and microbial colonization restored them (De Vadder & Associates, 2018). Additionally, gut bacteria support the growth of Mice's intestinal glial cells are crucial for preserving gut homeostasis regulation and neural networks (Kabouridis 2015). The way that intestinal neurons function can be impacted chemically by the intestinal microbiome communication, as demonstrated by a recent research demonstrating in mature mice, aryl hydrocarbon receptor activation can impact the gut via having an impact on the ENS, motility (Obata et al., 2020).

Gut microbiota and neurological Disorders

Alterations in the gut microbiota's composition have been linked to neurological and neuropsychiatric illnesses (Cryan et al., 2019; Tian et al., 2023). Neurological diseases are conditions affecting the central and peripheral nerve system that might cause damage to the spinal cord, brain, peripheral and cranial nerves, the autonomic nervous system, and nerve neuromuscular plaque and roots. Various circumstances can result in brain hemorrhage, including blood vessel illnesses and disorders resulting from defects in the development of the neurological system, damage to the brain tumors, spinal cord, and brain (Dugger and Dickson, 2017). Numerous neurological conditions are linked to dysbiosis of the microbiome of the human gut (Frank et al., 2007). Thus, the composition of the microbiota, which evolves over time, may have implications in brain function. In this Perspective, we review Recent developments in the field of neuromicrobiology, particularly the links between the gut microbiota and neurological disease. In exploring the role that gut microbes play in neurological disorders, we specifically focused on ASD, AD, PD, depression, and Anxiety disorders.

Alzheimer's disease

About 50 million individuals worldwide suffer with Alzheimer's disease (AD), which is the most prevalent cause of progressive, chronic, irreversible neurological illness as well as the most common kind of dementia in senior citizens. As the illness worsens, symptoms that negatively impact memory and cognitive

processes include jeopardize even the most fundamental everyday tasks (Scheltens et al., 2016) loss of neurons and deterioration with time AD symptoms include synaptic impairment (Tiraboschi et al., 2004). AD is brought on by the accumulation of soluble forms of polymerized β -amyloid precursor protein ($A\beta$) deposits of insoluble or multimeric amyloid in the brain that cause a series of unhealthy occurrences that result in neurofibrillary tangles, clusters of tau proteins that have been hyperphosphorylated, creation of neurofibrillary abnormalities, and eventually dementia (Scheltens et al., 2016).

Stool samples from AD patients had reduced levels of Firmicutes and Actinobacteria and increased levels of Bacteroidetes when compared to controls. Turicibacteraceae, Ruminococcaceae, AD patients had members of the Firmicutes families, including and Clostridiaceae reduced quantities (Vogt et al., 2017). Based on many research reports, there could be connections between the pathophysiology and mechanisms of AD and additional microorganisms including fungus, spirochaetes, and Chlamydia pneumoniae (Stojkovi et al., 2020; Lim et al., 2014). In current research, the etiology of AD has also been linked to the gut microbiome. An protein produced from the metabolite microbiota discovered in the cerebral fluid of AD patients and linked to two biomarkers associated with the condition (tau phosphorylation and tau phosphorylation/A-42) increases the likelihood that the genesis of AD is influenced by the gut microbiota (Vogt and others, 2018). When fecal microbiomes and fecal SCFAs were compared at different ages between AD-affected mice and wild-type mice, significant increases in Proteobacteria and Verrucomicrobia and there were noticeable drops in Ruminococcus and Butyricoccus. in AD mice, suggesting changed diversity and composition of the microbiota. The lower SCFA level further suggests changes in several metabolic processes (Zhang and colleagues, 2017). Furthermore, germ-free APP/PS1 transgenic animals exhibit a remarkable decrease in the degree of cerebral β -amyloid pathology in comparison to healthy control mice with gut microbiota (Harach et al., 2017). Bäuerl et al. (2018) revealed comparable results regarding the change in the makeup of the microbiota in the transgenic APP/PS1 mouse model which displays a rise in the quantity of the closely linked inflammatory family Erysipelotrichaceae. Additionally, germ-free APP/PS1 mice exhibited reduced amyloid pathology in contrast to normal mice (Radde and others, 2006).

Anxiety and depression

A quarter of the world's population suffers from mental and neurological diseases such as anxiety and depression. It appears that these two clinical disorders are closely associated: in fact, 85% of individuals with 90% of those with anxiety disorders and those who suffer sadness both significant anxiety (Maiuolo et al., 2021; Bui and Fava, 2017). Although these diseases' latter phases have

markedly distinct clinical indications (Koolhoven & Groeneweg, 2017). fatalities from teenage suicide have grown in the last several decades because to the growth in depressed symptoms (Jorm and colleagues, 2017). Numerous studies have examined the connection between anxiety and depression and modifications to the stability and make-up of the gut microbiota (Tognini, 2016). Recently, a number of research have emphasized the connection between the gut microbiome and those who have mood and anxiety issues. More specifically, data from studies on humans has shown that while taking taxonomic compositions and microbiological diversity into consideration, there is common for patients' fecal microbiota to differ in certain ways and wholesome safeguards. Furthermore, it was discovered that certain bacteria were associated with clinical characteristics and inflammatory or metabolic profiles.(Huang and others, 2019).

While considerable research has been done on human microbiome diversity, most of it has not been able to establish a link between low microbiome diversity and depressive illnesses (Chen and colleagues, 2014). Even though only one research shown that those with significant depression (MDD) showed increased gut alpha diversity compared to those in good health, alpha diversity is the quantity of species that are observable in an ecosystem of microbes (Jiang et al., 2015). Another research found that probiotics (*Lactobacillus acidophilus*, *Bifidobacterium bifidum*, and *Lactobacillus casei*) significantly decreased depression in MDD patients relative to a placebo in terms of symptoms (Akkasheh et al., 2016). The ability of microorganisms to generate the compound 3,4-dihydroxyphenylacetic acid a dopamine metabolite that positively connects with mental health Fecal metagenomic data indicate that there is a chance that Microbes are involved in the synthesis of several neuroactive molecules compared to normal circumstances during a depressive episode (VallesColomer et al., 2019). GABA is released by *Lactobacillus rhamnosus* and stimulates the brain's GABA receptors, namely GABA A α 2 and GABA B1b receptors) and has been demonstrated to lessen depressive symptoms and mouse behaviors resembling anxiety (Bravo et al., 2011).

Autism spectrum disorder

The neurological development abnormalities known as autism spectrum disorder (ASDs) are characterized by challenges with social interaction and communication as well as stereotyped and repetitive behavior (Maiuolo & associates, 2021). diarrhea, constipation, and stomach discomfort Among those with ASD, intestinal gas and farts are prevalent issues (23–70%) and commonly coexist with gastrointestinal disorders health conditions (Mulle et al., 2013). In ASD, the amounts of chemical transmitters such glutamate, oxytocin, GABA, and serotonin 5-HT complex are mediated by the gut flora. Because ASD patients have low-grade inflammation, microbiological effects on the immune

system could potentially be crucial in identifying neuroimmune answers in ASD. The application of new technology is happening quite quickly growing area of study when it becomes clear how much microbiological metabolites, such as SCFAs, bile acid metabolites, and taurine. The effects of 5-aminovaleric acid on symptoms of ASD (Morais et al., 2021). .. Although it cannot be said that these neurological problems are caused by a reduction in helpful bacteria and an increase in harmful germs, it is clear that Some microorganisms are linked to and compatible with the onset of ASD. (Vázquez Iglesias et al., 2020). The metabolites of the gut microbiota might have a critical role in the pathogenesis of ASD (Xu et al, 2019).

Clinical Implications

Fecal Microbiota Transplantation (FMT)It has been demonstrated that Fecal Microbiota Transplantation (FMT) can stop the progression of MS56 and seizures(Zhang T, et al,2017) for a considerable amount of time and can also momentarily lessen the symptoms of Parkinson's disease (PD), such as neuroinflammation and leg tremors (Metz et al,2018). Additionally, excrement transferred from Senescence-resistant mice in models of AD animals revealed enhancement of memory and learning in space (Runia TF, et al,2017). But there are still a lot of unknowns about FMT vague descriptions of a beneficial microbiome and a need to confirm its advantages and long-term impacts, particularly in light of its capacity to spread germs that both promote illness and immunological regulation. To deal with consequently, a number of clinical trials have been started, including one with the title "Fecal Microbiota: Safety and Efficacy."Transplantation in a Bipolar Disordered Population It aimed to concurrently look at the FMT's effects on clinical indicators linked to anxiety and depression aswell as its safety and tolerance for use in patients.In general, the substantial potential using FMT in bringing about a favorable improvement in the gut Patients' disease-related microbiome composition is offset. By the vagueness of it. Going ahead, it continues to whether FMT will be adequate as a stand-alone Treatment; probably, the response to it will rely on the unique characteristics of the microorganisms and the illness which adjust them.

Antibiotics Antibiotics have a significant impact on gut flora composition, which in turn affects immunological response and therapeutic effectiveness. About gliomas,Antibiotics, for instance, are necessary to prevent or treating people with illnesses that might be fatal from immunosuppression brought on by microbes and other negative consequences brought on by dangerous germs. In general, better tumor management may be possible if the right antibiotics are used to target the gut microbiota. Even as a direct treatment, antibiotics might be utilized, with the antibiotic clofocetol, which was just shown to suppress the formation of gliomas by glioma stem cell proliferation by means of increased K

appel-like component, a gene that suppresses tumors (Zhang et al, 2019). But extreme caution is required since antibiotics can harm the variety of the gut microbiota unintentionally, which can lead to neurological disorders. Different investigations shown that receiving broad-spectrum antibiotic therapy reduced cognitive function⁶¹ in mice of the wild type as well include elevated death rates and instances of severe colitis in mice after inducing strokes (Yang et al, 2018). One more research found that after receiving antibiotics, the incidence of vancomycin-resistant microorganisms rose, including like *Enterococcus faecium*, which raised the risk of patient death and bloodstream infections (Gregory et al, 2017). A new clinical initiative called "Microbiota Intervention to Change the Response of Parkinson's Disease" aims to look at the use of the antibiotic Rifaximin in lowering potentially harmful bacterial populations and reducing clinical signs of Parkinson's disease, such as blood indicators of inflammation. All things considered, it's clear that there is a need to use the microbiota's effects and expertise while developing new drugs or antibiotics.

Probiotics Probiotics are frequently found in foods and supplements that we regularly eat, such as yogurt. There have been an increasing number of "designer probiotics" introduced that have been genetically modified to the advantages of some microorganisms and are frequently incorporated into more conventional drug delivery systems (Barry et al, 2017). Crucially, several researches have indicated the advantages official effects in *Bifidobacteria* probiotic administration together with *Lactobacillus*, which raises GABA levels, neurotropic factor expression containing decreased seizures that occur in individuals with drug-resistant epilepsy, (Lai W, et al 2018) improvement of spatial impairments memory and learning in AD patients (via a combination of fermented milk), (Kakhaki et al, 2016) as well as a decrease in dopaminergic neurodegeneration and motor impairment in MitoPark PD mice models (Hsieh et al, 2020)

Diet Even if it's not always a therapeutic intervention, nutrition is important, especially in light of the growing body of research showing that drastic dietary modifications may quickly affect the microbial composition of the gut. Actually, a Prebiotics are a particular dietary class that has been identified which are fibers that cannot be digested (such as resistant starch, fructo-oligosaccharides, and galacto-oligosaccharides) specifically used as the main source of nourishment for gut microbes to provide health advantages. Frequently present in cereals, fruits, vegetables, and Prebiotics included in human milk have the benefit of influencing the gut flora more widely. For instance, dietary fiber reductions dramatically lower the abundance of *Faecalibacterium*, which boosts immunity SCFA butyrate and *prausnitzii*, which provide support intestinal well-being. On the other hand, an animal-based diet heavy in fat and low in fiber led to a drop in the

number of helpful metabolic bacteria and an increase in bile-tolerant microorganisms.

(Carmody et al 2014). In connection with this, there exist synbiotics, which consist of probiotics and prebiotics, with the prebiotics are utilized to improve the viability of the probiotic and supplement (by offering a source of fermentable fiber),⁴ and postbiotics, which are bacterial fermentation byproducts that include useful, bioactive substances gastrointestinal peptides and SCFAs, for example. Even though there's still the fact that postbiotics are nonviable organisms offers a clear benefit in the requirement for more defined targets greater safety and longer shelf life than probiotics profile (Huang et al, 2016). Importantly, it has been observed that higher-fiber diets resulted in greater diversity richness of the Gut microbiota and a higher abundance of favorable Taxa as well as increased butyrate production, which plays neuroprotective roles and enhances neuron plasticity. Not surprisingly, diet plays a significant role in outcomes associated with CNS disorders (Figure 3). Deciphering the ways in which the microbiota and treatment response interact will probably be the catalyst for the next major shift in the pharmaceutical development pipelines; it is not hyperbole to suggest that Soon, it would be commonplace for medications intended for humans to be examined for effects on the populations of microbes

Conclusion and future directions

The host's health and disease states depend on the gut microbiome, however the majority of the study on this topic to yet has only shown correlations between certain clinical illnesses and characteristics of bacteria. The gut microbiome significantly affects the brain's physiology and pathophysiology as a result of the relationship in both cases between the nervous system and the gut guidelines. Numerous channels are involved in this communication, including the vagal nerve, neuroendocrine systems, central nervous system neurotransmitters, and inflammatory agents. The Preclinical and clinical data are used to form the discussed evidence research on the dysbiosis of the gut microbiota and its correlation with the emergence and advancement of neurological disorders anomalies in neurodevelopment related to Parkinson's and depression illnesses, even if pinpointing their precise mechanism of action necessitates. Further investigation and probiotic supplementation are beneficial in the encouraging treatment options for neurological conditions. Probiotic supplement treatments are useful instruments with significant therapeutic promise for neurological illnesses; nevertheless, further study is needed to precisely identify their method of action.

Future research in this area could provide light on the relationship between the CNS and the microbiota, as well as advancements in the therapy for neurological conditions. The disciplines of microorganisms and neurology has to keep working, just like




Figure 3. Microbials modulate the development and treatment of CNS disorders. Microorganisms can promote production of essential metabolites, neurotransmitters, and other neuroactive compounds that influence the progression or treatment of various CNS diseases. In the setting of dysbiosis, increased prevalence of *Helicobacter Pylori* and *Escherichia coli*, for example, was shown to induce the progression of many neurological disorders and symptoms including the hyperphosphorylation of tau protein and amyloid-Beta load (indicative of Alzheimer's disease), α -Synuclein aggregation and Decrease motor performance (indicative of Parkinson's disease), and increased proinflammatory toxins and genotoxic metabolites (indicative of CNS malignancies).

other fields together to create comprehensive and relevant techniques to determine mechanisms of action underlying the current results observant, as well as conscientious attempts to translate these breakthroughs to enhance human health. significant populations in the world are experiencing neurological conditions, which should growth of 13% by 2030. Given the pathogenicity of the illnesses, it is imperative to find more accurate biomarkers and workable treatment alternatives. Several investigations have revealed that the GM is essential to the growth and operation of the brain. In many of studies include preclinical and clinical investigations, the GIT microbiota in The GBA has been examined about its correlation with several neurological conditions such epilepsy, stroke, PD, AD, MS, and ASD, plus cerebral damage. But further investigation is required to comprehend the role and mode of action of GM in illness pathogenesis and its potential use in future medical forecasting objectives. Despite recent advancements in our comprehension of the GBA, more investigation is necessary to ascertain whether or not this information may be useful in a therapeutic setting. upcoming research must make clear the fundamental connections between the GM and different neurological conditions and assess if managing the treatment with bacteria is secure and efficient. It might be able to create methods that specifically target the gut microbiome to provide cutting-edge, secure, and effective treatment choices for neurodegenerative illnesses in case conventional brain illnesses are considered in its whole and as current situations with a important function for the digestive tract.

Author Contributions

S.C. drafted the manuscript and made substantial contributions to the design of the study. L.E.A.H., S.M. reviewed and drafted the paper.

Acknowledgment

The authors are thankful to their university to support this study.

Competing financial interests

The author has no conflict of interest.

References

- Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., and Mazmanian, S. K. (2019). Microbiome microglia connections via the gut-brain axis. *J. Exp. Med.* 216, 41–59.
- Adams, J. B., Johansen, L. J., Powell, L. D., Quig, D., and Rubin, R. A. (2011). Gastrointestinal flora and gastrointestinal status in children with autism comparisons to typical children and correlation with autism severity. *BMC Gastroenterol.* 11, 1–13.
- Aizawa, E., Tsuji, H., Asahara, T., Takahashi, T., Teraishi, T., Yoshida, S., et al. (2016). Possible association of *Bifidobacterium* and *Lactobacillus* in the gut microbiota of patients with major depressive disorder. *J. Affect. Disord.* 202, 254–257.
- Akbari E, Asemi Z, Daneshvar Kakhaki R, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. *Front Aging Neurosci.* 2016;8:256.
- Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., et al. (2016). Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. *Front. Aging Neurosci.* 8:256.
- Akira, S., and Hemmi, H. (2003). Recognition of pathogen-associated molecular patterns by TLR family. *Immunol. Lett.* 85, 85–95.
- Akkasheh, G., Kashani-Poor, Z., Tajabadi-Ebrahimi, M., Jafari, P., Akbari, H., Taghizadeh, M., et al. (2016). Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. *Nutrition* 32, 315–320.
- Aktar, R., Parkar, N., Stentz, R., Baumard, L., Parker, A., Goldson, A., et al. (2020). Human resident gut microbe *Bacteroides thetaiotaomicron* regulates colonic neuronal innervation and neurogenic function. *Gut Microbes* 11, 1745–1757.
- Al Omran, Y., and Aziz, Q. (2014). The brain-gut axis in health and disease. *Microbial Endocrinol.* 817, 135–153.
- Alvarez, E., Martinez, M. D., Roncero, I., Chowen, J. A., Garcia-Cuartero, B., Gisbert, J. D., et al. (2005). The expression of GLP1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. *J. Neurochem.* 92, 798–806.
- Alzheimer's, A. (2016). Alzheimer's disease facts and figures. *Alzheimers Dement.* 12, 459–509.
- Aresti Sanz, J., and El Aidy, S. (2019). Microbiota and gut neuropeptides: a dual action of antimicrobial activity and neuroimmune response. *Psychopharmacology* 236, 1597–1609.
- Askarova, S., Umbayev, B., Masoud, A. R., Kaiyrykyzy, A., Safarova, Y., Tsoy, A., et al. (2020). The links between the gut microbiome, aging, modern lifestyle and Alzheimer's disease. *Front. Cell. Infect. Microbiol.* 10:104.
- Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al. (2011). Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science* 331, 337–341.
- Baj, A., Moro, E., Bistoletti, M., Orlandi, V., Crema, F., and Giaroni, C. (2019). Glutamatergic signaling along the microbiota-gut-brain axis. *Int. J. Mol. Sci.* 20:1482.
- Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., et al. (2019). Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. *Mov. Disord.* 34, 396–405.
- Bastiaanssen, T. F. S., Cowan, C. S. M., Claesson, M. J., Dinan, T. G., and Cryan, J. F. (2019). Making sense of the microbiome in psychiatry. *Int. J. Neuropsychopharmacol.* 22, 37–52.
- Bäuerl, C., Collado, M. C., Diaz Cuevas, A., Vifia, J., and Martínez, G. P. (2018). Shifts in gut microbiota composition in an APP/PSS 1 transgenic mouse model of Alzheimer's disease during lifespan. *Lett Appl Microbiol.* 66, 464–471.

- Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., et al. (2011a). The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice. *Gastroenterology* 141:e593, 599–609.e3.
- Bercik, P., Park, A. J., Sinclair, D., Khoshdel, A., Lu, J., Huang, X., et al. (2011b). The anxiolytic effect of *Bifidobacterium longum* NCC3001 involves vagal pathways for gut-brain communication. *J Gastrointestinal Motility* 23, 1132–1139.
- Bercik, P., Verdu, E. F., Foster, J. A., Macri, J., Potter, M., Huang, X., et al. (2010). Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. *Gastroenterology* 139:e2101.
- Berding, K., and Donovan, S. M. (2016). Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs. *Nutr. Rev.* 74, 723–736
- Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., et al. (2017). Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. *PNAS* 114, 10719–10724.
- Bhargava, P., and Mowry, E. M. (2014). Gut microbiome and multiple sclerosis. *Curr. Neurol. Neurosci. Rep.* 14, 1–8.
- Bhattarai, Y., Si, J., Pu, M., Ross, O. A., McLean, P. J., Till, L., et al. (2021). Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease. *Gut Microbes* 13:1866974.
- Bibbo, S., Dore, M. P., Pes, G. M., Delitala, G., and Delitala, A. P. (2017). Is there a role for gut microbiota in type 1 diabetes pathogenesis? *Ann. Med.* 49, 11–22.
- Blacher, E., Bashiardes, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., et al. (2019). Potential roles of gut microbiome and metabolites in modulating ALS in mice. *Nature* 572, 474–480.
- Blandini, F., Nappi, G., Tassorelli, C., and Martignoni, E. (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. *Prog. Neurobiol.* 62, 63–88.
- Blaser, M. J. (2017). The theory of disappearing microbiota and the epidemics of chronic diseases. *Nat. Rev. Immunol.* 17, 461–463.
- Boertien, J. M., Pereira, P. A. B., Aho, V. T. E., and Scheperjans, F. (2019). Increasing comparability and utility of gut microbiome studies in Parkinson's disease: a systematic review. *J. Parkinsons Dis.* 9, S297–S312.
- Braniste, V., al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., et al. (2014). The gut microbiota influences blood–brain barrier permeability in mice. *Sci. Transl. Med.* 6:263ra158.
- Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., et al. (2011). Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *PNAS* 108, 16050–16055.
- Brun, P., Giron, M. C., Qesari, M., Porzionato, A., Caputi, V., Zoppellaro, C., et al. (2013). Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. *Gastroenterology* 145, 1323–1333.
- Bu, X. L., Yao, X. Q., Jiao, S. S., Zeng, F., Liu, Y. H., Xiang, Y., et al. (2015). A study on the association between infectious burden and Alzheimer's disease. *Eur. Neurol.* 22, 1519–1525
- Bui, E., and Fava, M. (2017). From depression to anxiety, and back. *Acta Psychiatr. Neurol. Scand.* 136, 341–342.
- Burberry, A., Wells, M. F., Limone, F., Couto, A., Smith, K. S., Keaney, J., et al. (2020). C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. *Nature* 582, 89–94.
- Capuron, L., and Miller, A. H. (2011). Immune system to brain signaling: neuropsychopharmacological implications. *Pharm. Therap.* 130, 226–238.
- Carabotti, M., Scirocco, A., Maselli, M. A., and Severi, C. (2015). The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Annals Gastroenterol* 28:203.
- Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proc Natl Acad Sci U S A.* 2017;114 (40):10713–10718.
- Cekanaviciute, E., Yoo, B. B., Runia, T. F., Debelius, J. W., Singh, S., Nelson, C. A., et al. (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *PNAS* 114, 10713–10718.
- Cersosimo, M. G., Raina, G. B., Pecci, C., Pellene, A., Calandra, C. R., Gutiérrez, C., et al. (2013). Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. *J. Neurol* 260, 1332–1338.
- Chen, J., Chia, N., Kalari, K. R., Yao, J. Z., Novotna, M., Paz Soldan, M. M., et al. (2016). Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci. Rep.* 6, 1–10.
- Chen, Y., Xu, J., and Chen, Y. (2021). Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. *Nutrients* 13:2099.
- David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature.* 2014;505 (7484):559–563.
- He Z, Cui BT, Zhang T, et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn's disease: the first report. *World J Gastroenterol.* 2017;23(19):3565–3568.
- Heijtz, R. D., Wang, S., Anuar, F., Qian, Y., Björkholm, B., Samuelsson, A., et al. (2011). Normal gut microbiota modulates brain development and behavior. *PNAS* 108, 3047–3052.
- Heinzel, S., Aho, V. T. E., Suenkel, U., von Thaler, A. K., Schulte, C., and Deuschle, C. (2021). Gut microbiome signatures of risk and prodromal markers of Parkinson disease. *Ann. Neurol.* 90, E1–E12.
- Hill-Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., et al. (2017). Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. *Mov. Disord.* 32, 739–749.
- Hirayama, M., and Ohno, K. (2021). Parkinson's disease and gut microbiota. *Ann. Nutr. Metab.* 77, 28–35.
- Ho, L. K. H., Tong, V. J. W., Syn, N., Nagarajan, N., Tham, E. H., Tay, S. K., et al. (2020). Gut microbiota changes in children with autism spectrum disorder: a systematic review. *Gut Pathogens* 12, 1–18.
- Hsiao, E. Y., McBride, S. W., Hsien, S., Sharon, G., Hyde, E. R., McCue, T., et al. (2013). Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cells* 155, 1451–1463.

- Hsieh TH, Kuo CW, Hsieh KH, et al. Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease. *Brain Sci.* 2020;10(4).
- Hu Y, Zhang M, Tian N, et al. The antibiotic clofocetol suppresses glioma stem cell proliferation by activating KLF13. *J Clin Invest.* 2019;129(8):3072–3085.
- Huang, C., Wang, J., Hu, W., Wang, C., Lu, X., Tong, L., et al. (2016). Identification of functional farnesoid X receptors in brain neurons. *FEBS Lett.* 590, 3233–3242.
- Huang, Q., Di, L., Yu, F., Feng, X., Liu, Z., Wei, M., et al. (2022). Alterations in the gut microbiome with hemorrhagic transformation in experimental stroke. *CNS Neurosci. Ther.* 28, 77–91.
- Huang, T. T., Lai, J. B., Du, Y. L., Xu, Y., Ruan, L. M., and Hu, S. H. (2019). Current understanding of gut microbiota in mood disorders: an update of human studies. *Front. Genet.* 10:98.
- Hube, F., Lietz, U., Igel, M., Jensen, P. B., Tornqvist, H., Joost, H. G., et al. (1996). Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. *Horm. Metab. Res.* 28, 690–693.
- Iannone, L. F., Preda, A., Blottière, H. M., Clarke, G., Albani, D., Belcastro, V., et al. (2019). Microbiota-gut brain axis involvement in neuropsychiatric disorders. *Expert. Rev. Neurother.* 19, 1037–1050.
- Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome.* 2017;5(1):10
- Lim B, Zimmermann M, Barry NA, Goodman AL. Engineered regulatory systems modulate gene expression of human commensals in the gut. *Cell.* 2017;169(3):547–558.e15.
- Liu WH, Chuang HL, Huang YT, et al. Alteration of behavior and monoamine levels attributable to *Lactobacillus plantarum* PS128 in germ-free mice. *Behav Brain Res.* 2016;298(Pt B):202–209.
- Makkawi S, Camara-Lemarroy C, Metz L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. *Neurol Neuroimmunol Neuroinflamm.* 2018;5(4):e459.
- Peng A, Qiu X, Lai W, et al. Altered composition of the gut microbiome in patients with drug-resistant epilepsy. *Epilepsy Res.* 2018;147:102–107.
- Zhan G, Yang N, Li S, et al. Abnormal gut microbiota composition contributes to cognitive dysfunction in SAMP8 mice. *Aging.* 2018;10(6):1257–1267. (Albany NY).